| [1] |
Sherwood E, Vergnano S, Kakuchi I, Bruce MG, Chaurasia S, David S, et al. Invasive group A streptococcal disease in pregnant women and young children: a systematic review and meta-analysis. Lancet Infect Dis. 2022; 22(7): 1076-88.
doi: 10.1016/S1473-3099(21)00672-1
pmid: 35390294
|
| [2] |
Stevens DL, Tanner MH, Winship J, Swarts R, Ries KM, Schlievert PM, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989; 321(1): 1-7.
|
| [3] |
Davies MR, Keller N, Brouwer S, Jespersen MG, Cork AJ, Hayes AJ, et al. Detection of Streptococcus pyogenes M1UK in Australia and characterization of the mutation driving enhanced expression of superantigen SpeA. Nat Commun. 2023;14: 1051.
|
| [4] |
Harris K, Proctor LK, Shinar S, Philippopoulos E, Yudin MH, Murphy KE. Outcomes and management of pregnancy and puerperal group A streptococcal infections: a systematic review. Acta Obstet Gynecol Scand. 2023; 102(2): 138-57.
|
| [5] |
Arai T, Takai Y, Samejima K, Matsunaga S, Ono Y, Seki H. How could we suspect life-threatening perinatal group A streptococcal infection? J Obstet Gynaecol Res. 2020; 46(12): 2573-81.
|
| [6] |
Carapetis JR, Jacoby P, Carville K, Ang SJ, Curtis N, Andrews R. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group A streptococcal infections. Clin Infect Dis. 2014; 59(3): 358-65.
doi: 10.1093/cid/ciu304
pmid: 24785239
|
| [7] |
Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014; 59(6): 851-7.
doi: 10.1093/cid/ciu449
pmid: 24928291
|
), Xiaoxia Bai1,5,6(
